- CROSS Trial, page 1
- Neoadjuvant chemoradiation vs surgery alone
- Carboplatin and Paclitaxel + radiotherapy 40g in 23F for 5 weeks
- Surgery within 4-6/52 post
- Inclusions
- T1/N1, or T2/T3 NO or N1
- Oesophageal and GOJ cancers (22% SCC, 75% adeno)
- Results
- 368 patients
- Significantly higher R0 resection (56 vs 90%)
- 5yr survival advantage
- 46% vs 36%
- Overall survival longer 48m vs 24m
- SCC 80m vs 50m
- Adenocarcinoma 40m and 28m
- Results not as good for adenocarcinoma as they are for SCC